+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 217 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
50 locations
T

Actively Recruiting

Researchers are conducting a prospective, longitudinal, non-interventional multicenter study involving participants with head and neck squamous cell carcinoma HNSCC. The study focuses on patients with metastatic or unresectable recurrent HNSCC who are planned to receive first-line immunotherapy or combination therapy. This study aims to explore molecular biomarkers from tissue and blood samples to better understand prognostic and predictive markers, and to guide future biomarker research. Participants will not receive any experimental treatment as this is an observational study. Instead, molecular profiling will be done using tumor tissue and blood samples collected during their standard of care. The study plans to include up to 500 participants with tumors located in the pharynx, larynx, oral cavity, or oropharynx. There is no intervention, and participants will continue their planned first-line anti-PD1 or PDL1 therapy or combination treatment. Throughout the five-year study period, researchers will collect longitudinal blood samples and diagnostic or progression biopsy samples to examine changes in DNA, RNA, immune markers, and circulating tumor DNA ctDNA. These assessments aim to understand real-world outcomes, resistance mechanisms, and evaluate ctDNA as a response biomarker. Participants will provide informed consent, and their compliance with study procedures, including blood sample collection, will be monitored.

Age: 18Years +All Genders
32 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
R

Actively Recruiting

Researchers are evaluating BNT324 compared to the standard chemotherapy docetaxel combined with prednisone or prednisolone in men with metastatic castration-resistant prostate cancer mCRPC who have been previously treated with androgen receptor pathway inhibitors but have not received taxane-based chemotherapy for mCRPC. This phase III trial aims to determine if BNT324 can help participants live longer without their cancer worsening and improve overall survival. Participants are randomly assigned to one of two groups receiving BNT324 through intravenous infusion or receiving docetaxel intravenously along with oral prednisone or prednisolone. Treatment is given in 21-day cycles and continues until the cancer progresses, side effects become unacceptable, the participant decides to stop, or the study concludes. The study includes a screening period lasting up to 28 days, followed by treatment and an after-treatment period that includes a 30-day safety follow-up and a long-term survival follow-up. Participants will undergo assessments including scans reviewed centrally to monitor cancer progression, laboratory tests such as PSA levels, and evaluation of side effects. Researchers will track outcomes like radiographic progression-free survival and overall survival for up to approximately 58 months. Safety is closely monitored by an independent committee, and participants continue regular follow-up visits during and after treatment to assess response and manage any adverse events.

Age: 18Years +MALEPhase 3
52 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
G

Actively Recruiting

Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.

Age: 18Years +All GendersPhase 2Phase 3
42 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations

1-10 of 217

1